Transgenic Plant Expression of Smallpox Immunogenic Proteins
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current smallpox vaccines, particularly the live vaccine, pose safety concerns for certain populations and are not suitable for individuals with compromised immunity, pregnant women, the elderly, and infants, and there is a need for safer and more effective alternatives.
Innovation Solution
Development of transgenic plants expressing immunogenic proteins such as L1, B5, and A33, which are capable of eliciting an immune response against poxvirus, using expression cassettes and plant-derived compositions to produce immunogenic compositions that can be used for immunization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If live smallpox vaccine is used, then immunity against smallpox is achieved, but safety concerns arise for compromised immunity populations, pregnant women, elderly, and infants
Solution Approach 1:
The patent extracts only the essential immunogenic components (L1, B5, A33 proteins) from the live smallpox virus and expresses them as recombinant proteins in plant cells. This extraction eliminates the harmful live viral components while retaining the beneficial immunogenic properties, thereby resolving the contradiction between immunity effectiveness and safety risks.
Solution Approach 2:
The patent uses plant cells as an intermediary system to produce the immunogenic proteins. The plants serve as a safe third-party host that can express human immunogenic proteins without containing the actual pathogen, thus mediating between the need for effective immunity and the requirement for safety in vulnerable populations.
2Object-affected harmful factors
If plant-derived immunogenic compositions are used, then safety is improved for vulnerable populations, but manufacturing complexity increases due to transgenic plant development
Solution Approach 1:
The patent enables plants to serve themselves as production factories for the immunogenic proteins. By introducing the expression cassettes into plant cells, the plants autonomously express and accumulate the recombinant proteins in their tissues, eliminating the need for complex animal cell culture facilities and simplifying the manufacturing process.
Solution Approach 2:
The patent uses transgenic plants that can simultaneously serve multiple functions: as the expression system for producing immunogenic proteins, as a containment system ensuring safety, and as a scalable production platform. This multi-functionality reduces overall manufacturing complexity compared to specialized biopharmaceutical production systems.
3Ease of manufacture
If traditional vaccine production methods are used, then established protocols are available, but scalability and cost-effectiveness are limited
Solution Approach 1:
The patent transitions from traditional two-dimensional cell culture systems to three-dimensional plant tissue systems for protein production. Plants can be grown in large volumes and scaled up agriculturally, providing a third dimension of scalability that overcomes the production limits of conventional vaccine manufacturing while maintaining protocol simplicity through agricultural practices.
Data Source
AI summary
Compositions and methods for producing plant-derived immunogenic compositions that confer immunity against smallpox in a subject are provided. Plants engineered to produce antigenic proteins as well as expression cassettes comprising nucleic acids encoding proteins thereof are described. Methods of immunizing subjects with plant-derived compositions are also provided.